KYKathryn E. Yost

Kathryn E. Yost

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kathryn E. Yost has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report

    by Jason D. Goldman, Kai Wang, Katharina Röltgen, Sandra C. A. Nielsen, Jared C. Roach, Samia N. Naccache, Fan Yang, Oliver F. Wirz, Kathryn E. Yost, Ji-Yeun Lee, et al.

    Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 144 days in a single patient, to conclusively describe reinfection with a different strain harboring the spike variant D614G. This case of reinfection was one of the first cases of reinfection reported in 2020. With antibody, B cell and T cell analytics, we show correlates of adaptive immunity at reinfection, including a differential response in neutralizing antibodies to a D614G pseudovirus. Finally, we discuss implications for vaccine programs and begin to define benchmarks for protection against reinfection from SARS-CoV-2.


  • Open Access

    Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report

    by Jason D. Goldman, Kai Wang, Katharina Röltgen, Sandra C. A. Nielsen, Jared C. Roach, Samia N. Naccache, Fan Yang, Oliver F. Wirz, Kathryn E. Yost, Ji-Yeun Lee, et al.

    Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 140 days in a single patient, to conclusively describe reinfection with a new strain harboring the spike variant D614G. With antibody and B cell analytics, we show correlates of adaptive immunity, including a differential response to D614G. Finally, we discuss implications for vaccine programs and begin to define benchmarks for protection against reinfection from SARS-CoV-2.


  • Open Access

    Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2

    by Sandra Cathrine Abel Nielsen, Fan Yang, Katherine J. L. Jackson, Ramona A. Hoh, Katharina Röltgen, Bryan Stevens, Ji-Yeun Lee, Arjun Rustagi, Angela J. Rogers, Abigail E. Powell, et al.

    SUMMARY: During virus infection B cells are critical for the production of antibodies and protective immunity. Here we show that the human B cell compartment in patients with diagnostically confirmed SARS-CoV-2 and clinical COVID-19 is rapidly altered with the early recruitment of B cells expressing a limited subset of IGHV genes, progressing to a highly polyclonal response of B cells with broader IGHV gene usage and extensive class switching to IgG and IgA subclasses with limited somatic hypermutation in the initial weeks of infection. We identify extensive convergence of antibody sequences across SARS-CoV-2 patients, highlighting stereotyped naïve responses to this virus. Notably, sequence-based detection in COVID-19 patients of convergent B cell clonotypes previously reported in SARS-CoV infection predicts the presence of SARS-CoV/SARS-CoV-2 cross-reactive antibody titers specific for the receptor-binding domain. These findings offer molecular insights into shared features of human B cell responses to SARS-CoV-2 and other zoonotic spillover coronaviruses.


  • Open Access

    Spen links RNA-mediated endogenous retrovirus silencing and X chromosome inactivation

    by Ava C. Carter, Jin Xu, Meagan Y. Nakamoto, Yuning Wei, Quanming Shi, James P. Broughton, Ryan C. Ransom, Ankit Salhotra, Surya D. Nagaraja, Rui Li, et al.

    Dosage compensation between the sexes has emerged independently multiple times during evolution, often harnessing long noncoding RNAs (lncRNAs) to alter gene expression on the sex chromosomes. In eutherian mammals, X chromosome inactivation (XCI) in females proceeds via the lncRNAXist, which coats one of the two X chromosomes and recruits repressive proteins to epigenetically silence gene expressionin cis1,2. HowXistevolved new functional RNA domains to recruit ancient, pleiotropic protein partners is of great interest. Here we show that Spen, anXist-binding repressor protein essential for XCI3-7, binds to ancient retroviral RNA, performing a surveillance role to recruit chromatin silencing machinery to these parasitic loci.Speninactivation leads to de-repression of a subset of endogenous retroviral (ERV) elements in embryonic stem cells, with gain of chromatin accessibility, active histone modifications, andERVRNA transcription. Spen binds directly toERVRNAs that show structural similarity to the A-repeat ofXist, a region critical forXist-mediated gene silencing8-9.ERVRNA andXistA-repeat bind the RRM3 domain of Spen in a competitive manner. Insertion of an ERV into an A-repeat deficientXistrescues binding ofXistRNA to Spen and results in local gene silencingin cis. These results suggest that insertion of an ERV element into proto-Xistmay have been a critical evolutionary event, which allowedXistto coopt transposable element RNA-protein interactions to repurpose powerful antiviral chromatin silencing machinery for sex chromosome dosage compensation.

  • Open Access

    Clonal replacement of tumor-specific T cells following PD-1 blockade

    by Kathryn E. Yost, Ansuman T. Satpathy, Daniel K. Wells, Yanyan Qi, Chunlin Wang, Robin Kageyama, Katherine McNamara, Jeffrey M. Granja, Kavita Y. Sarin, Ryanne A. Brown, et al.

    Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the clinical care of cancer patients. However, which tumor-specific T cells are mobilized following checkpoint blockade remains unclear. Here, we performed paired single-cell RNA- and T cell receptor (TCR)-sequencing on 79,046 cells from site-matched tumors from patients with basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) pre- and post-anti-PD-1 therapy. Tracking TCR clones and transcriptional phenotypes revealed a coupling of tumor-recognition, clonal expansion, and T cell dysfunction: the T cell response to treatment was accompanied by clonal expansions of CD8 + CD39 + T cells, which co-expressed markers of chronic T cell activation and exhaustion. However, this expansion did not derive from pre-existing tumor infiltrating T cell clones; rather, it comprised novel clonotypes, which were not previously observed in the same tumor. Clonal replacement of T cells was preferentially observed in exhausted CD8 + T cells, compared to other distinct T cell phenotypes, and was evident in BCC and SCC patients. These results, enabled by single-cell multi-omic profiling of clinical samples, demonstrate that pre-existing tumor-specific T cells may be limited in their capacity for re-invigoration, and that the T cell response to checkpoint blockade relies on the expansion of a distinct repertoire of T cell clones that may have just recently entered the tumor.


  • Open Access

    Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion

    by Ansuman T. Satpathy, Jeffrey M. Granja, Kathryn E. Yost, Yanyan Qi, Francesca Meschi, Geoffrey P. McDermott, Brett N. Olsen, Maxwell R. Mumbach, Sarah E. Pierce, M. Ryan Corces, et al.

    Understanding complex tissues requires single-cell deconstruction of gene regulation with precision and scale. Here we present a massively parallel droplet-based platform for mapping transposase-accessible chromatin in tens of thousands of single cells per sample (scATAC-seq). We obtain and analyze chromatin profiles of over 200,000 single cells in two primary human systems. In blood, scATAC-seq allows marker-free identification of cell type-specific cis - and trans -regulatory elements, mapping of disease-associated enhancer activity, and reconstruction of trajectories of differentiation from progenitors to diverse and rare immune cell types. In basal cell carcinoma, scATAC-seq reveals regulatory landscapes of malignant, stromal, and immune cell types in the tumor microenvironment. Moreover, scATAC-seq of serial tumor biopsies before and after PD-1 blockade allows identification of chromatin regulators and differentiation trajectories of therapy-responsive intratumoral T cell subsets, revealing a shared regulatory program driving CD8 + T cell exhaustion and CD4 + T follicular helper cell development. We anticipate that droplet-based single-cell chromatin accessibility will provide a broadly applicable means of identifying regulatory factors and elements that underlie cell type and function.